Kocabaş, U.Ergin, I.Yavuz, V.Murat, S.Özdemir, I.Genç, Ö.Altın, C.2024-08-252024-08-2520231308-4488https://doi.org/10.5543/tkda.2022.98455https://hdl.handle.net/11454/101609OBJECTIVE: Oral anticoagulant therapy is the cornerstone of atrial ?brillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial ?brillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial ?brillation. METHODS: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial ?brillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. RESULTS: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2-VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. CONCLUSIONS: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial ?brillation.time in therapeutic range with <70%.en10.5543/tkda.2022.98455info:eu-repo/semantics/openAccessanticoagulant agentdabigatrandipyronerivaroxabanvitamin K groupadultagedatrial fibrillationcerebrovascular accidentclinical trialcomplicationembolismfemalehumanmalemiddle agedmulticenter studyoral drug administrationprospective studyvery elderlyyoung adultAdministration, OralAdultAgedAged, 80 and overAnticoagulantsAtrial FibrillationDabigatranEmbolismFemaleHumansMaleMiddle AgedProspective StudiesPyridonesRivaroxabanStrokeVitamin KYoung AdultArticle51288962-s2.0-8515031127336916815Q4